Malone JI, Hansen BC. Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite? Pediatr Diabetes. 2019;20:5–9.
Article
PubMed
Google Scholar
Finkelstein EA, Khavjou OA, Thompson H, Trogdon JG, Pan L, Sherry B, Dietz W. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42:563–70.
Article
PubMed
Google Scholar
Unamuno X, Gómez-Ambrosi J, Rodríguez A, Becerril S, Frühbeck G, Catalán V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. 2018;48:e12997.
Article
PubMed
CAS
Google Scholar
Friedman J. The long road to leptin. J Clin Invest. 2016;126:4727–34.
Article
PubMed
PubMed Central
Google Scholar
Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin. 2018;39:1176–88.
Article
CAS
PubMed
PubMed Central
Google Scholar
D’Souza AM, Neumann UH, Glavas MM, Kieffer TJ. The glucoregulatory actions of leptin. Mol Metab. 2017;6:1052–65.
Article
PubMed
PubMed Central
CAS
Google Scholar
Frias JP, Bastyr EJ 3rd, Vignati L, Tschöp MH, Schmitt C, Owen K, Christensen RH, DiMarchi RD. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab. 2017;26:343–52.e342.
Article
CAS
PubMed
Google Scholar
Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, Ren J, Davies MJ. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32–7.
Article
CAS
PubMed
Google Scholar
Sardu C, D’Onofrio N, Torella M, Portoghese M, Loreni F, Mureddu S, Signoriello G, Scisciola L, Barbieri M, Rizzo MR, et al. Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin. Cardiovasc Diabetol. 2019;18:126.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kotsis V, Jordan J, Stabouli S, Antza C, Micic D, Jelaković B, Schlaich MP, Nilsson PM, Kreutz R, Mancia G, et al. Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. J Hypertens. 2020;38:377–86.
Article
CAS
PubMed
Google Scholar
Home P. Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia. 2019;62:357–69.
Article
CAS
PubMed
Google Scholar
Zhou P, Xie W, He S, Sun Y, Meng X, Sun G, Sun X. Ginsenoside Rb1 as an anti-diabetic agent and its underlying mechanism analysis. Cells. 2019;8(3):204.
Article
CAS
PubMed Central
Google Scholar
Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res. 2018;122:1439–59.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lamos EM, Hedrington M, Davis SN. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opin Drug Saf. 2019;18:691–701.
Article
CAS
PubMed
Google Scholar
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32.
Article
CAS
PubMed
Google Scholar
Flier JS. Starvation in the midst of plenty: reflections on the history and biology of insulin and leptin. Endocr Rev. 2019;40:1–16.
Article
PubMed
Google Scholar
German JP, Wisse BE, Thaler JP, Oh IS, Sarruf DA, Ogimoto K, Kaiyala KJ, Fischer JD, Matsen ME, Taborsky GJ Jr, et al. Leptin deficiency causes insulin resistance induced by uncontrolled diabetes. Diabetes. 2010;59:1626–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cernea S, Both E, Huţanu A, Şular FL, Roiban AL. Correlations of serum leptin and leptin resistance with depression and anxiety in patients with type 2 diabetes. Psychiatry Clin Neurosci. 2019;73:745–53.
Article
CAS
PubMed
Google Scholar
Huerta MG. Adiponectin and leptin: potential tools in the differential diagnosis of pediatric diabetes? Rev Endocr Metab Disord. 2006;7:187–96.
Article
CAS
PubMed
Google Scholar
Denroche HC, Levi J, Wideman RD, Sequeira RM, Huynh FK, Covey SD, Kieffer TJ. Leptin therapy reverses hyperglycemia in mice with streptozotocin-induced diabetes, independent of hepatic leptin signaling. Diabetes. 2011;60:1414–23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Friedman JM. Leptin and the endocrine control of energy balance. Nat Metab. 2019;1:754–64.
Article
CAS
PubMed
Google Scholar
López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, Triana-Cubillos S. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig. 2014;18:37–45.
PubMed
Google Scholar
Liu X, Men P, Wang Y, Zhai S, Liu G. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Lipids Health Dis. 2016;15:204.
Article
PubMed
PubMed Central
CAS
Google Scholar
Scheen AJ. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: results of randomized controlled trials and observational studies. Diabetes Metab. 2018;44:386–92.
Article
CAS
PubMed
Google Scholar
Kohno D, Furusawa K, Kitamura T. Anagliptin suppresses diet-induced obesity through enhancing leptin sensitivity and ameliorating hyperphagia in high-fat high-sucrose diet fed mice. Endocr J. 2020;67:523–9.
Article
CAS
PubMed
Google Scholar
Marques AP, Cunha-Santos J, Leal H, Sousa-Ferreira L, Pereira de Almeida L, Cavadas C, Rosmaninho-Salgado J. Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice. Biochim Biophys Acta Gen Subj. 2018;1862:403–13.
Article
CAS
PubMed
Google Scholar
Li S, Li H, Wang R, Zhang JP. The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus. Eur Rev Med Pharmacol Sci. 2017;21:3490–5.
CAS
PubMed
Google Scholar
Osonoi T, Saito M, Hariya N, Goto M, Mochizuki K. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin. Peptides. 2016;86:118–25.
Article
CAS
PubMed
Google Scholar
Pérez-Pérez A, Sánchez-Jiménez F, Vilariño-García T, Sánchez-Margalet V. Role of leptin in inflammation and vice versa. Int J Mol Sci. 2020;21(16):5887.
Article
PubMed Central
CAS
Google Scholar
Ziegler JF, Böttcher C, Letizia M, Yerinde C, Wu H, Freise I, Rodriguez-Sillke Y, Stoyanova AK, Kreis ME, Asbach P, et al. Leptin induces TNFα-dependent inflammation in acquired generalized lipodystrophy and combined Crohn’s disease. Nat Commun. 2019;10:5629.
Article
CAS
PubMed
PubMed Central
Google Scholar
Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, Yovos JG, Karamitsos D. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets. 2011;15:401–20.
Article
CAS
PubMed
Google Scholar
Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, Didangelos TP, Yovos JG, Karamitsos DT. Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptidey levels in patients with type 2 diabetes mellitus: a pilot study. Open Cardiovasc Med J. 2011;5:136–47.
Article
CAS
PubMed
PubMed Central
Google Scholar
Prakash S, Rai U, Kosuru R, Tiwari V, Singh S. Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice. Biochimie. 2020;168:198–209.
Article
CAS
PubMed
Google Scholar
Fukuda-Tsuru S, Kakimoto T, Utsumi H, Kiuchi S, Ishii S. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Eur J Pharmacol. 2014;723:207–15.
Article
CAS
PubMed
Google Scholar
Shinjo T, Nakatsu Y, Iwashita M, Sano T, Sakoda H, Ishihara H, Kushiyama A, Fujishiro M, Fukushima T, Tsuchiya Y, et al. DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation. Am J Physiol Endocrinol Metab. 2015;309:E214–23.
Article
CAS
PubMed
Google Scholar
Liu X, Men P, Wang B, Cai G, Zhao Z. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. Lipids Health Dis. 2019;18:144.
Article
PubMed
PubMed Central
CAS
Google Scholar
Takeshita Y, Takamura T, Kita Y, Takazakura A, Kato K, Isobe Y, Kaneko S. Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study. Int J Endocrinol. 2015;3:e000122.
Google Scholar
Takeshita Y, Takamura T, Kita Y, Otoda T, Kato K, Wakakuri H, Yamada M, Misu H, Matsushima Y, Kaneko S. Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: a randomized, parallel-group study. J Diabetes investig. 2015;6:192–200.
Article
CAS
PubMed
Google Scholar
Kato H, Nagai Y, Ohta A, Tenjin A, Nakamura Y, Tsukiyama H, Sasaki Y, Fukuda H, Ohshige T, Terashima Y, Sada Y, Kondo A, Sasaoka T, Tanaka Y. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;1:199–205.
Article
CAS
Google Scholar
Matsushima Y, Takeshita Y, Kita Y, Otoda T, Kato K, Toyama-Wakakuri H, Akahori H, Shimizu A, Hamaguchi E, Nishimura Y, Kanamori T, Kaneko S, Takamura. T:Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial. BMJ Open Diabetes Res Care. 2016;4:e000190.
Article
PubMed
PubMed Central
Google Scholar
Dore FJ, Domingues C, Ahmadi C, Kundu N, Kropotova N, Houston Y, Rouphael S, Mammadova C, Witkin A, Khiyami L, Amdur A, Sen RL. S: The synergistic effects of saxagliptin and metformin on CD34 + endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial. Cardiovasc Diabetol. 2018;17:65.
Article
CAS
PubMed
PubMed Central
Google Scholar
Takihata, MTerauchi, Y. The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study. Expert Opin Pharmacother. 2019;17:2185–94.
Google Scholar
Takeshita Y, Kita Y, Kato KI, Kanamori T, Misu H, Kaneko S, Takamura T. Effects of metformin and alogliptin on body composition in people with type 2 diabetes. J Diabetes Investig. 2019;10:723–30.
Article
CAS
PubMed
Google Scholar
Schiapaccassa A, Maranhão PA, de Souza, Mdgc, Panazzolo DG, Nogueira Neto JF, Bouskela E, Kraemer-Aguiar L. G:30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and obesity: a randomized head-to-head metformin-controlled study. Diabetol Metab Syndr. 2019;11:70.
Article
PubMed
PubMed Central
CAS
Google Scholar
Awal HB, Nandula SR, Domingues CC, Dore FJ, Kundu N, Brichacek B, Fakhri M, Elzarki A, Ahmadi N, Safai S, Fosso M, Amdur RL, Sen S. Linagliptin, when compared to placebo, improves CD34 + ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial. Cardiovasc Diabetol. 2020;19:72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Komorizono Y, Hosoyamada K, Imamura N, Kajiya S, Hashiguchi Y, Ueyama N, Shinmaki H, Koriyama N, Tsukasa M, Kamada T. Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: an analysis of the J-LINK study. Diabetes Obes Metab. 2021;23:832–7.
Article
CAS
PubMed
Google Scholar